| 产品描述: | ACT-451840 是一种具有口服活性,强效低毒化合物,对敏感和耐药的恶性疟原虫株具有活性。ACT-451840 对 parasite 的所有无性血液阶段,起效快速。ACT-451840 的作用方式与青蒿素衍生物类似,具有非常迅速消除 parasite 的作用。ACT-451840 可以用于研究疟疾 。 |
| 体外研究: |
ACT-451840 shows a 50 % inhibition concentration of 0.4 nM against the drug-sensitive P. falciparum NF54 strain. The IC50 value of ACT-451840 against the murine malaria parasite P. berghei is 13.5 nM in in vitro ex vivo assays. |
| 体内研究: |
ACT-451840 (10 and 60 mg kg) starts to show significant antimalarial effects (parasite reduction) in vivo at 20 mg/kg. ACT-451840 exhibits curative activity at 300 mg/kg and significant antimalarial effects already at 100 mg/kg. ACT-451840 shows excellent reduction at 30 mg/kg, resulting in 99.80 % activity. ACT-451840 shows efficacy in the Plasmodium berghei mouse model. |
| 参考文献: |
1. Bruderer S, et al. First-in-humans study of the safety, tolerability, and pharmacokinetics of ACT-451840, a new chemical entity with antimalarial activity. Antimicrob Agents Chemother. 2015;59(2):935-942.
2. Boss C, et al. Discovery and Characterization of ACT-451840: an Antimalarial Drug with a Novel Mechanism of Action. ChemMedChem. 2016;11(18):1995-2014.
3. Le Bihan A, et al. Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling. PLoS Med. 2016;13(10):e1002138. Published 2016 Oct 4. |
| 溶解性: |
soluble in DMSO |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.332 ml |
6.658 ml |
13.316 ml |
| 5 mM |
0.266 ml |
1.332 ml |
2.663 ml |
| 10 mM |
0.133 ml |
0.666 ml |
1.332 ml |
| 50 mM |
0.027 ml |
0.133 ml |
0.266 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |